세계의 소아용 백신 개발 시장 규모 : 유형별, 기술별, 용도별, 지역별 범위 및 예측

Pediatric Vaccines Development Market Size And Forecast

Pediatric Vaccines Development Market size was valued at USD 31.4 Billion in 2024 and is projected to reach USD 68.6 Billion by 2032, growing at a CAGR of 10.3% from 2026 to 2032.

The rising popularity of technology-driven platforms for self-growth amongst millennials is also expected to positively impact market growth during the forecast period. Increasing awareness regarding vaccines and immunization among the populace is expected to boost the growth of the global Pediatric Vaccines Development Market over the forecast period. The Global Pediatric Vaccines Development Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Pediatric Vaccines Development Market Drivers

The market drivers for the Pediatric Vaccines Development Market can be influenced by various factors. These may include:

Growing Knowledge and Focus on Preventive Healthcare: The need for paediatric vaccines is being driven by parents' and healthcare professionals' growing understanding of the value of immunisation in preventing childhood illnesses.

Government Initiatives and Immunisation Programmes: Growing access to vaccinations, especially in developing nations, is being facilitated by government-led immunisation programmes and initiatives.

The development of new adjuvants, delivery systems, and recombinant DNA techniques is among the technological advancements in vaccine research that are speeding up the development of paediatric vaccines and enhancing their efficacy and safety profiles.

Growing Incidence of Infectious Diseases: The demand for paediatric vaccination is being driven by the persistent incidence of infectious diseases in children, including measles, influenza, pneumonia, and meningitis.

More Funding for Vaccine Research and Development: Growing investments in paediatric vaccine research and development from governments, nonprofits, and pharmaceutical corporations are stimulating innovation and propelling market expansion.

Increasing Vaccination Coverage: Worldwide demand for paediatric vaccinations is being driven by initiatives to raise vaccination coverage rates, such as catch-up vaccination programmes and regular immunisation schedules.

Threats from Emerging Infectious Diseases: The rise in threats from emerging infectious diseases, such the Ebola and Zika viruses, emphasises the significance of ongoing attempts to produce vaccines to address changing public health issues.

Emphasis on Disease Eradication and Elimination: Demand for paediatric vaccinations is being driven by global measures to eradicate or reduce vaccine-preventable illnesses like measles and polio, which is bolstering the growth of the market.

The promotion of vaccination as a public health intervention is being aided by the advocacy efforts of international health organisations, paediatricians, and other healthcare professionals. This has led to a rise in the acceptance and uptake of paediatric vaccines.

Technological and Manufacturing Advancements: The development of cell culture-based and recombinant vaccine production platforms, among other vaccine manufacturing technologies, is increasing the scalability, efficiency, and cost-effectiveness of vaccines and propelling their market expansion.

Global Pediatric Vaccines Development Market Restraints

Several factors can act as restraints or challenges for the Pediatric Vaccines Development Market. These may include:

Strict Regulatory Requirements: The lengthy and strict regulatory approval procedures for paediatric vaccines frequently cause delays in the development of new products and the launch of new products.

High Development expenses: Smaller biotechnology businesses and academic institutions may find it difficult to innovate and remain competitive in the market due to the high expenses involved in developing paediatric vaccines, which include research and clinical trials.

Limited Market Potential for Rare disorders: It can be expensive to create vaccines for rare paediatric disorders when there may not be a significant return on investment to cover development expenses.

Misinformation and Vaccine reluctance: Misinformation and vaccine mistrust can cause vaccine reluctance, which can obstruct immunisation campaigns, lower demand for paediatric vaccinations, and hamper market expansion.

Cold Chain requirements: It can be logistically difficult and expensive to maintain the cold chain for vaccine distribution and storage, particularly in rural and resource-constrained places. This can have an influence on vaccination accessibility and adoption.

Intellectual property rights and patent issues: Concerns over vaccination technology and development can give rise to legal battles and market entry delays, which can impede innovation and competition.

Disruptions in the vaccine supply chain, such as problems with manufacturing, shortages of raw materials, or difficulties with distribution, can affect the stability of the market and result in supply shortages.

Global Health Equity Challenges: Inequalities in high- and low-income nations' access to paediatric vaccines might worsen global health disparities by restricting market expansion and impeding attempts to attain universal immunisation coverage.

Safety worries and Adverse Events: The public's trust and confidence in vaccination programmes can be damaged by safety worries and reports of adverse events linked to paediatric vaccinations. This can result in a decline in vaccine uptake and market demand.

Competition from Established Vaccines: In crowded vaccine markets, it can be difficult for novel vaccines to obtain market share due to competition with established paediatric vaccines with well-known safety and effectiveness characteristics.

Global Pediatric Vaccines Development Market Segmentation Analysis

The Global Pediatric Vaccines Development Market is Segmented Based on Type, Technology, Application, And Geography.

Pediatric Vaccines Development Market, By Type

• Monovalent
• Multivalent

Based on Type, The market is bifurcated into Monovalent, Multivalent. The Monovalent segment is expected to inflate the market growth owing to their safety and stability and their ability to develop a rapid immune response.

Pediatric Vaccines Development Market, By Technology

• Live Attenuated
• Inactivated
• Subunit
• Toxoid
• Conjugate
• Others

Based on Technology, The market is bifurcated into Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate, Others. The Conjugate segment is expected to inflate the market growth. This can be attributed to an increase in the prevalence of pneumococcal and meningococcal infections and a rise in awareness regarding the prevention of diseases.

Pediatric Vaccines Development Market, By Application

• Infectious Disease
• Cancer
• Allergy

Based on Application, The market is bifurcated into Infectious Disease, Cancer, and Allergy. Infectious Disease is anticipated to become the fastest-growing market in the forecast duration due to growing global awareness about immunization against a number of infectious diseases that cause mortality and morbidity.

Pediatric Vaccines Development Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world
• On the basis of Geography, The Global Pediatric Vaccines Development Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America is expected to hold the largest market share in the forecast period. Some of the key factors that can be attributed to its dominance are an increase in R&D investments by numerous companies and a rise in government support for immunization and the development of pediatric vaccines. In addition, the presence of advanced healthcare infrastructure and facilities for immunization supports the growth of this segment.

Key Players

The "Global Pediatric Vaccines Development Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are GlaxoSmithKline plc, Merck Sharp & Dohme Corp., SANOFI, AstraZeneca, Pfizer, Inc., Zydus Cadila, Indian Immunologicals Limited, Serum Institute of India Pvt. Ltd., Mitsubishi Tanabe Pharma Corporation, and Panacea Biotec. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL PEDIATRIC VACCINES DEVELOPMENT MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL PEDIATRIC VACCINES DEVELOPMENT MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL PEDIATRIC VACCINES DEVELOPMENT MARKET, BY TYPE

• 5.1 Overview
• 5.2 Monovalent
• 5.3 Multivalent

6 GLOBAL PEDIATRIC VACCINES DEVELOPMENT MARKET, BY TECHNOLOGY

• 6.1 Overview
• 6.2 Live Attenuated
• 6.3 Inactivated
• 6.4 Subunit
• 6.5 Toxoid
• 6.6 Conjugate
• 6.7 Others

7 GLOBAL PEDIATRIC VACCINES DEVELOPMENT MARKET, BY APPLICATION

• 7.1 Overview
• 7.2 Infectious Disease
• 7.3 Cancer
• 7.4 Allergy

8 GLOBAL PEDIATRIC VACCINES DEVELOPMENT MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East & Africa

9 GLOBAL PEDIATRIC VACCINES DEVELOPMENT MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 GlaxoSmithKline plc
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Merck Sharp & Dohme Corp.
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 SANOFI
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 AstraZeneca
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Pfizer, Inc.
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Zydus Cadila
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Indian Immunologicals Limited
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Serum Institute of India Pvt. Ltd.
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Mitsubishi Tanabe Pharma Corporation
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Panacea Biotec
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 Appendix

• 11.1 Related Research